Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLUE NASDAQ:IGMS NASDAQ:MNPR NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$6.47-6.6%$5.01$3.50▼$12.40$399.59M1.42771,379 shs3.60 million shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AMNPRMonopar Therapeutics$57.00+4.6%$39.67$3.90▼$58.94$351.69M1.239,895 shs76,445 shsSCPHscPharmaceuticals$5.62+0.2%$5.11$1.94▼$6.28$299.55M0.35611,908 shs944,975 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+44.07%+44.38%+51.31%+51.64%+13.98%IGMSIGM Biosciences0.00%0.00%0.00%+6.72%-89.67%MNPRMonopar Therapeutics+10.71%+31.36%+52.59%+59.79%+1,311.66%SCPHscPharmaceuticals-0.36%+0.54%+21.96%+40.60%+2.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$6.47-6.6%$5.01$3.50▼$12.40$399.59M1.42771,379 shs3.60 million shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AMNPRMonopar Therapeutics$57.00+4.6%$39.67$3.90▼$58.94$351.69M1.239,895 shs76,445 shsSCPHscPharmaceuticals$5.62+0.2%$5.11$1.94▼$6.28$299.55M0.35611,908 shs944,975 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+44.07%+44.38%+51.31%+51.64%+13.98%IGMSIGM Biosciences0.00%0.00%0.00%+6.72%-89.67%MNPRMonopar Therapeutics+10.71%+31.36%+52.59%+59.79%+1,311.66%SCPHscPharmaceuticals-0.36%+0.54%+21.96%+40.60%+2.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33136.99% UpsideIGMSIGM Biosciences 1.89Reduce$4.89284.95% UpsideMNPRMonopar Therapeutics 3.00Buy$71.7525.88% UpsideSCPHscPharmaceuticals 2.00Hold$7.7838.49% UpsideCurrent Analyst Ratings BreakdownLatest IGMS, MNPR, SCPH, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.009/15/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$87.009/9/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$87.009/3/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$77.009/2/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$80.008/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.358/27/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$74.008/26/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.008/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/13/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLUEMonte Rosa Therapeutics$75.62M5.28N/AN/A$3.63 per share1.78IGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ASCPHscPharmaceuticals$36.33M8.25N/AN/A$0.27 per share20.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLUEMonte Rosa Therapeutics-$72.70M$0.3617.97N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)IGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)Latest IGMS, MNPR, SCPH, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/7/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 million7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLUEMonte Rosa TherapeuticsN/A7.167.16IGMSIGM BiosciencesN/A17.6617.66MNPRMonopar TherapeuticsN/A33.9333.93SCPHscPharmaceuticals3.863.853.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLUEMonte Rosa Therapeutics79.96%IGMSIGM Biosciences42.79%MNPRMonopar Therapeutics1.83%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipGLUEMonte Rosa Therapeutics6.50%IGMSIGM Biosciences57.00%MNPRMonopar Therapeutics20.50%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLUEMonte Rosa Therapeutics9061.76 million57.75 millionOptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableIGMS, MNPR, SCPH, and GLUE HeadlinesRecent News About These CompaniesSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHSeptember 16 at 12:17 PM | businesswire.comShort Interest in scPharmaceuticals, Inc. (NASDAQ:SCPH) Drops By 48.2%September 16 at 7:53 AM | marketbeat.comCorstasis scores FDA nod for nasal spray treatment, touts sales potentialSeptember 15 at 11:56 PM | fiercepharma.comFscPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest UpdateSeptember 11, 2025 | marketbeat.com90,503 Shares in scPharmaceuticals, Inc. $SCPH Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comscPharmaceuticals, Inc. $SCPH Position Reduced by Deutsche Bank AGSeptember 3, 2025 | marketbeat.comApis Capital Advisors LLC Grows Holdings in scPharmaceuticals, Inc. $SCPHSeptember 2, 2025 | marketbeat.comMannKind diversifies pipeline with $360M buySeptember 2, 2025 | pacbiztimes.comPKingdon Capital Management L.L.C. Buys 200,000 Shares of scPharmaceuticals, Inc. $SCPHSeptember 1, 2025 | marketbeat.comH.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)August 31, 2025 | finance.yahoo.comVelan Capital Investment Management LP Makes New Investment in scPharmaceuticals, Inc. $SCPHAugust 31, 2025 | marketbeat.comMaxim Group Reaffirms Hold Rating for scPharmaceuticals (NASDAQ:SCPH)August 27, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at MaximAugust 26, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...August 26, 2025 | tmcnet.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHAugust 26, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of ShareholdersAugust 26, 2025 | globenewswire.comStonepine Capital Management LLC Has $914,000 Stock Holdings in scPharmaceuticals, Inc. $SCPHAugust 26, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at Craig-HallumAugust 25, 2025 | msn.comCT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M dealAugust 25, 2025 | hartfordbusiness.comHMannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M dealAugust 25, 2025 | fiercepharma.comFSCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKindAugust 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGMS, MNPR, SCPH, and GLUE Company DescriptionsMonte Rosa Therapeutics NASDAQ:GLUE$6.47 -0.46 (-6.64%) Closing price 04:00 PM EasternExtended Trading$6.50 +0.04 (+0.54%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.IGM Biosciences NASDAQ:IGMS$1.27 0.00 (0.00%) As of 08/14/2025IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Monopar Therapeutics NASDAQ:MNPR$57.00 +2.51 (+4.61%) Closing price 04:00 PM EasternExtended Trading$56.90 -0.10 (-0.18%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.scPharmaceuticals NASDAQ:SCPH$5.62 +0.01 (+0.18%) Closing price 04:00 PM EasternExtended Trading$5.62 +0.00 (+0.09%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
